Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 11/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.59 |
| ▸ | PGR | P06401 | 5/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | AR | P10275 | 2/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | IL6 | P05231 | 1/20 | 0.59 |
| ▸ | GLUL | P15104 | 1/20 | 0.59 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.59 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28286516 | 1.00 | HIF1A (0.60) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL7145318 | 1.00 | HIF1A (0.60) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL7142740 | 1.00 | HIF1A (0.60) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL7986 | 0.99 | HIF1A (0.60) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL677626 | 0.98 | HIF1A (0.61) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL27700555 | 0.94 | HIF1A (0.59) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL11068491 | 0.94 | HIF1A (0.62) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL945988 | 0.93 | HIF1A (0.65) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL27977292 | 0.92 | HIF1A (0.60) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL264554 | 0.92 | HIF1A (0.64) | HIF1ASMN1; SMN2MAPTPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144021-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2025-05-08 | — | — | US | claimed |
| US-20220175955-A1 | PEPTIDE DISPLAY TO ANTIGEN PRESENTING CELLS USING LIPID VEHICLE | DANMARKS TEKNISKE UNIVERSITET (DK) | 2022-06-09 | — | — | US | claimed |
| CN-112703199-A | Displaying peptides on antigen presenting cells using lipid carriers | 转矩医疗股份有限公司 | 2021-04-23 | — | — | CN | claimed |
| EP-3794019-A1 | PEPTIDE DISPLAY TO ANTIGEN PRESENTING CELLS USING LIPID VEHICLE | Torque Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | claimed |
| WO-2016079332-A1 | GEL FORMULATIONS FOR IMPROVING IMMUNOTHERAPY | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2016-05-26 | — | — | WO | claimed |
| CN-104703588-A | Cationic liposome delivery system for specific targeting of human CD14+ monocytes in whole blood | BIONEER AS | 2015-06-10 | — | — | CN | claimed |
| US-20150079155-A1 | Cationic Liposomal Drug Delivery System for Specific Targeting of Human CD14+ Monocytes in Whole Blood | BIONEER A/S (DK) | 2015-03-19 | — | — | US | claimed |
| EP-2825158-A1 | CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD | Bioneer A/S (DK) | 2015-01-21 | — | — | EP | claimed |
| WO-2013135800-A1 | CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD | BIONEER A/S (DK) | 2013-09-19 | — | — | WO | claimed |
| EP-2638896-A1 | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood | Bioneer A/S (DK) | 2013-09-18 | — | — | EP | claimed |
| EP-0041772-B2 | FAT EMULSION CONTAINING A STEROID | GREEN CROSS CORPORATION (JP) | 1990-04-18 | — | — | EP | claimed |
| EP-0041772-B1 | FAT EMULSION CONTAINING A STEROID | GREEN CROSS CORPORATION (JP) | 1984-10-17 | — | — | EP | claimed |
| US-4340594-A | Fat emulsion containing steroid | THE GREEN CROSS CORPORATION (JP) | 1982-07-20 | — | — | US | claimed |
| EP-0041772-A2 | Fat emulsion containing a steroid | GREEN CROSS CORPORATION (JP) | 1981-12-16 | — | — | EP | claimed |
| US-20250144021-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2025-05-08 | — | — | US | disclosed |
| EP-4529477-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| EP-4529468-A1 | FORMULATION OF API'S AND EXCIPIENT'S IN AN ICELL VIA HYDROPHOBIC ION PAIRING | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| EP-0041772-B1 | FAT EMULSION CONTAINING A STEROID | GREEN CROSS CORPORATION (JP) | 1984-10-17 | — | — | EP | disclosed |
| US-4340594-A | Fat emulsion containing steroid | THE GREEN CROSS CORPORATION (JP) | 1982-07-20 | — | — | US | disclosed |
| EP-0041772-A2 | Fat emulsion containing a steroid | GREEN CROSS CORPORATION (JP) | 1981-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144021-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TREH, GALE, SLC2A8 | HIF1A 2738/4885SMN1; SMN2 3060/4885MAPT 1633/4885 |
| US-20220175955-A1 | PEPTIDE DISPLAY TO ANTIGEN PRESENTING CELLS USING LIPID VEHICLE | CD74, MICA, TAP1 | HIF1A 3241/4885SMN1; SMN2 3510/4885MAPT 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.